Clinical utility of targeted next generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making.

Mary Jane Lim-FatGilbert C YoussefMehdi TouatJ Bryan IorgulescuSydney WhorralMarie AllenRifaquat RahmanUgonma ChukwuekeJ Ricardo McFaline-FigueroaLakshmi NayakEudocia Q LeeTracy T BatchelorOmar ArnaoutPier Paolo PeruzziE Antonio ChioccaDavid A ReardonDavid MeredithSandro SantagataRameen BeroukhimWenya Linda BiKeith L LigonPatrick Y Wen

Published in: Neuro-oncology (2021)

While NGS testing has become essential for improved molecular diagnostics, our study illustrates that targeted gene panels remain underutilized for selecting therapy in GBM-IDHwt. Targeted therapy and clinical trial design remain to be improved to help leverage the potential of NGS in clinical care.

Keyphrases

clinical trial
decision making
cancer therapy
copy number
palliative care
high throughput
genome wide
randomized controlled trial
stem cells
open label
quality improvement
bone marrow
cell therapy
phase ii
pain management
human health
wild type
genome wide identification